Enovid

E411214

Enovid was the first commercially available oral contraceptive pill, introduced in the 1960s and widely recognized for revolutionizing birth control and reproductive health.

All labels observed (1)

Label Occurrences
Enovid canonical 2

How this entity was disambiguated

Statements (47)

Predicate Object
instanceOf combination oral contraceptive
hormonal contraceptive
oral contraceptive pill
pharmaceutical drug
approvedBy Food and Drug Administration
surface form: U.S. Food and Drug Administration
associatedRisk cardiovascular side effects
increased risk of thromboembolic events
associatedWith changes in U.S. contraceptive regulation
early debates over contraceptive safety
containsHormoneType estrogen
progestin
containsSyntheticEstrogen mestranol
containsSyntheticProgestin norethynodrel
countryOfFirstApproval United States of America
surface form: United States
developedBy G. D. Searle & Company
estrogenComponent mestranol
FDAApprovalYear 1960
firstApprovedUse contraception
hasActiveIngredient mestranol
norethynodrel
historicalSignificance catalyst of the sexual revolution
influenced women’s rights movement
influencedDevelopmentOf later low-dose oral contraceptives
innovationType first-generation oral contraceptive
introducedDecade 1960s
legacy established oral contraception as a standard method of birth control
legalStatusAtApproval prescription-only medicine
manufacturer G. D. Searle & Company
marketImpact rapid adoption among women seeking reliable birth control
mechanismOfAction alteration of cervical mucus
changes in endometrial lining
inhibition of ovulation
notableFor first commercially available oral contraceptive pill
major impact on reproductive health
revolutionizing birth control
pharmaceuticalForm tablet
pharmacologicalClass steroid hormone preparation
previousIndication endometriosis
infertility related to ovulatory disorders
menstrual disorders
primaryEffect prevention of pregnancy
progestinComponent norethynodrel
reasonForWithdrawal safety concerns related to high hormone doses
regulatoryStatus withdrawn from market
routeOfAdministration oral
targetPopulation women of reproductive age
therapeuticClass combined estrogen–progestin contraceptive

How these facts were elicited

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.